AHA Coding Clinic® for HCPCS - 2020 Issue 4; For Your Information

New HCPCS Level II codes for monoclonal antibody therapies for COVID-19

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab, on November 9, 2020. On November 21, 2020, an EUA was issued for casirivimab and imdevimab (also known as REGN-COV2 or REGEN-COV2). Casirivimab and imdevimab are to be administered together. These monoclonal antibody therapies are for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization. The Centers for Medicare and Medicaid Services (CMS) has identified specific HCPCS Level II code(s) listed...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.

Thank you for choosing Find-A-Code, please Sign In to remove ads.